Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SMR 2024 | Fecal microbial transplantation combined with anti-PD-1 therapy in melanoma

Saman Maleki • 22 Oct 2024
SMR 2024
Melanoma Skin Cancer Antibodies Checkpoint Inhibitors Nivolumab Pembrolizumab

Saman Maleki, PhD, Lawson Health Research Institute, London, Canada, discusses a recent study on the combination of fecal microbial transplantation from healthy donors with immune checkpoint inhibitors for first-line melanoma treatment. A promising objective response rate was reported in patients receiving the fecal transplant in combination with either pembrolizumab or nivolumab. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Saman Maleki

Microbiome modulation strategies in melanoma therapy
1:28
Microbiome modulation strategies in melanoma therapy
Saman Maleki • 22 Oct 2024
Evaluating the role of gut and tumor microbiome in melanoma immunotherapy
1:17
Evaluating the role of gut and tumor microbiome in melanoma immunotherapy
Saman Maleki • 22 Oct 2024
IL-12 + IL-27 upregulate CD39 expression on CD8+ T-cells + affect CD39+CD8+ T-cell effector function
3:28
IL-12 + IL-27 upregulate CD39 expression on CD8+ T-cells + affect CD39+CD8+ T-cell effector function
Saman Maleki • 2 Nov 2022
Microbiome modification with fecal transplant before IO to reduce primary resistance in melanoma
4:17
Microbiome modification with fecal transplant before IO to reduce primary resistance in melanoma
Saman Maleki • 2 Nov 2022

Related Videos

Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
3:13
Advances in TIL therapy for melanoma and solid tumors highlighted at ASCO 2026
Omid Hamid • 30 May 2026
ASCO 2026: personalized vaccines and triplet immunotherapy in melanoma
1:32
ASCO 2026: personalized vaccines and triplet immunotherapy in melanoma
Omid Hamid • 30 May 2026
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
0:55
Melanoma immunotherapy strategies shape treatment approaches across solid tumors
Omid Hamid • 30 May 2026
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
1:18
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
Alexandra Haugh • 30 May 2026
The content of VJOncology is intended for healthcare professionals